CBD

Last updated: May 4, 2025

Cannabidiol, or CBD, is a natural compound found primarily in the flowers and leaves of the hemp plant, a variety of cannabis used historically for thousands of years. It works by interacting with your body's complex cell-signaling network known as the endocannabinoid system and is most known for potentially easing anxiety and improving sleep without the "high" associated with THC. While some studies, particularly using specific formulations like nanodispersible CBD, show significant improvements in mild to moderate anxiety, overall research presents mixed results, with systematic reviews often finding insufficient evidence for widespread mental health benefits, highlighting the need for more high-quality trials.

Table of Contents

Categories & Effectiveness
Dosage & Side Effects
Benefits by Use Case
Frequently Asked Questions
Summary & Expert Opinion
Research Studies

Back to All Nootropics

Categories & Effectiveness

Mood & Stress

Anxiety Relief

7/10

Strong evidence of effectiveness

Emotional Stability

4/10

Moderate evidence of effectiveness

Mood Elevation

4/10

Moderate evidence of effectiveness

Wellbeing Boost

4/10

Moderate evidence of effectiveness

Physical Performance

Appetite Regulation

4/10

Moderate evidence of effectiveness

Sleep Quality

Deeper Sleep Quality

4/10

Moderate evidence of effectiveness

Dosage & Side Effects

Recommended Dosage

Common dosages used in studies range widely, from 30mg up to 1200mg per day, often depending on the condition being studied and the formulation used. While an optimal dose isn't universally established, research suggests benefits for anxiety with specific formulations around 150mg/mL, though higher single doses (e.g., 300-600mg) have also been studied. Evidence for effectiveness in specific groups like cancer patients is currently insufficient, and use in young people is still under investigation.

Potential Side Effects

CBD is generally considered well-tolerated, with most studies reporting no serious adverse events, especially with moderate doses. Some research indicates that higher doses, particularly of synthetic THC sometimes combined with CBD, may increase the risk of anxiety or other adverse effects, although this is less clear for CBD isolate. Always start with a low dose to assess tolerance, and consult with a healthcare provider, especially if taking other medications, due to potential interactions.

Interactions & Stacks

While specific synergistic stacks involving only CBD aren't well-documented in the provided research, the ratio of CBD to THC is noted to influence effects in cannabis products. Caution is advised when combining CBD with high doses of THC, as some studies suggest this may increase anxiety events. Meta-analyses consistently point to mixed or inconclusive evidence regarding the effectiveness of cannabinoids for many mental health conditions, emphasizing the need for careful consideration and more research.

Benefits by Use Case

Mild Anxiety Relief

May help reduce symptoms of mild to moderate anxiety, as shown in some clinical trials using specific formulations. Evidence for broader anxiety disorders or severe cases is less consistent.

Sleep Quality Support

Can potentially improve sleep quality, often reported as a secondary benefit in anxiety studies. Effects may vary depending on the cause of sleep disturbance.

Appetite Support

Medicinal cannabis products (including those with CBD) have shown potential to improve appetite in some studies, particularly in cancer patients. This effect may be linked more strongly to THC or whole-plant extracts.

Cognitive Support

Considered an emerging strategy for addressing cognitive impairments, though research is still developing. High-quality evidence confirming significant cognitive benefits is currently limited.

Frequently Asked Questions

Is CBD addictive?

When should I take CBD?

Can CBD really help with anxiety?

Does CBD work for depression?

Is CBD safe to take?

Will CBD help me sleep better?

Can CBD help with cancer symptoms?

Summary & Expert Opinion

Overall, CBD shows clear promise, particularly for easing mild to moderate anxiety and improving sleep quality, supported by specific clinical trials like the one using a nanodispersible formulation. Its main strengths lie in its generally good safety profile and lack of intoxicating effects compared to THC, making it an appealing option for many. However, the research landscape is marked by inconsistency; systematic reviews often conclude there's insufficient high-quality evidence to firmly recommend CBD for many mental health conditions, including depression and stress, especially in specific populations like cancer patients. Individuals seeking relief from mild anxiety or sleep issues might find CBD beneficial after consulting a healthcare provider, while those with severe conditions or taking other medications should exercise caution due to limited robust evidence and potential interactions.

Research Studies

Showing 5 of 6 studies

Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials (2024)

cognitive impairments

Authors:

Adriana Yndart Arias

Findings:

Cannabidiol is presented as an emerging strategy for treating cognitive impairments, based on a review of randomized trials.

Study Quality Assessment:

Review of randomized trials.

Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial (2024)

anxiety reduction depression safety +2 more

Authors:

Arjun Narala, Chandrashekhar Kocherlakota, Kumar SD Kothapalli, Nagaraju Banda, Prasad Rao Gundugurti, Ramyasree Thatikonda, Siva Sankara Rao Yadlapalli

Findings:

Nanodispersible CBD significantly improved primary (GAD-7, HAM-A scores) and secondary outcomes (CGI-I, CGI-S, PHQ-9, PSQI scores) compared to placebo in treating mild to moderate anxiety disorders. The treatment was found to be therapeutically safe, well-tolerated, with no serious adverse events, and also effective for associated depression and sleep quality disturbances.

Participants:

N=178 participants with mild to moderate anxiety

Dosage:

Nanodispersible cannabidiol oral solution (150 mg/mL)

Study Quality Assessment:

Phase 3 prospective, randomized, double blind, parallel group, placebo-controlled, 15-week cohort study conducted at multiple sites. N=178. Conflict of interest declared for several authors affiliated with pharmaceutical companies.

All Effects:

anxiety reduction depression safety sleep quality tolerability

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder (2023)

A comprehensive systematic review and meta-analysis on the medicinal use of cannabinoids for depression, anxiety, PTSD, tic disorders, and psychosis (2019)

PTSD anxiety bipolar disorder +6 more

Authors:

Black et al.

Findings:

This review summarizes evidence on cannabinoid effects for major depression, bipolar disorder, anxiety, PTSD, and schizophrenia, suggesting therapeutic potential due to the endocannabinoid system's role in these conditions. However, the text concludes that current evidence supporting cannabinoid use for mental disorders is unconvincing due to study limitations (small samples, short duration, lack of follow-up), mixed results across studies, and potential harms associated with regular/heavy cannabis use. High-quality clinical trials are deemed necessary to confirm efficacy and safety.

Participants:

The text reviews studies involving various participants, including: medication-free women with major depression, patients treated with electroconvulsive therapy, suicide victims with/without psychiatric history, female patients with high comorbid anxiety, adults exposed to childhood trauma, psychiatric patients, general population members, bipolar patients (including type I), healthy adults/volunteers, patients with social anxiety disorder (SAD), drug-naive subjects with SAD, patients with generalized anxiety disorder, panic disorder, or agoraphobia, individuals with PTSD, psychiatric outpatients with PTSD, schizophrenic patients (including first-episode, treatment-refractory, stable outpatients), and individuals vulnerable to psychosis. Several ongoing clinical trials mentioned target specific groups like those with bipolar depression, various anxiety disorders, PTSD, or schizophrenia.

Dosage:

Specific dosages mentioned in reviewed studies or ongoing trials include: Bipolar: CBD (600-1200 mg/day oral; 150-300 mg/day for 12 weeks; 600 mg one-time oral), THC (2mg & 4mg vaporized), Dronabinol (5 mg one-time oral). Anxiety: CBD (400 mg single dose; 600 mg acute dose; 30 mg/day sublingual tincture for 4 weeks; 200-800 mg/day capsules for 8 weeks; 150-300 mg/day oil; up to 100 mg/day soft gels for 12 weeks), THC (7.5 mg oral - anxiolytic; 12.5 mg oral - increased negative mood). PTSD: THC (5 mg sublingual twice daily for 3 weeks), Dronabinol (5 mg & 10 mg), CBD (300 mg fixed dose oil). Schizophrenia: Dronabinol (2.5, 5, 10 mg increasing doses for 3 weeks), CBD (1000 mg adjunct for 6 weeks; 600 mg/daily adjunct for 6 weeks). Nabilone use mentioned for PTSD nightmares. Dose-dependent effects noted for THC in anxiety (low dose anxiolytic, high dose anxiogenic) and psychosis.

Study Quality Assessment:

The text describes itself as a review summarizing evidence. It mentions findings from various study types including: systematic reviews, meta-analyses, randomized controlled trials (RCTs, some double-blind, placebo-controlled), cross-sectional investigations, large-scale epidemiological studies, independent cohort studies, population-based longitudinal studies, open-label studies, case reports/series, controlled cohort studies, postmortem studies, genetic studies, and neuroimaging studies (SPECT, PET). Limitations acknowledged include: equivocal evidence for cannabis-based interventions, weak evidence for efficacy/safety in major depression, conflicting results potentially due to varying doses, THC/CBD content, and administration modes, limited and insufficient evidence for PTSD improvement, potential confounding by sample size/methodology differences in schizophrenia studies, and general limitations of existing clinical studies (small patient numbers, short duration, lack of reliable follow-up). Funding source acknowledged (University of Cagliari), and authors declared no conflict of interest.

All Effects:

PTSD anxiety bipolar disorder cognition depression mental disorders psychosis side effects therapeutic potential

This meta-analysis summarizes the effectiveness of cannabis and cannabinoids for managing medical and psychotic disorders

PTSD anxiety depression +2 more

Findings:

This review summarizes evidence for cannabinoid (natural/synthetic, THC/CBD) use in major depression, bipolar disorder, anxiety, PTSD, and schizophrenia, noting dysregulation of the endocannabinoid system in these conditions. While some studies and anecdotal reports suggest potential benefits (e.g., CBD for anxiety/psychosis; THC for PTSD nightmares), the overall evidence for therapeutic efficacy is considered unconvincing, weak, mixed, or equivocal. Risks associated with heavy/regular cannabis use (worsening symptoms, psychosis risk) are highlighted, and the need for more high-quality, large-scale clinical trials to confirm efficacy and safety is emphasized.

Participants:

The text reviews studies involving various participants including: patients with mental disorders (major depression, bipolar disorder, anxiety disorders, PTSD, schizophrenia), medication-free women with major depression, suicide victims, drug-naive subjects with social anxiety disorder, healthy adults/volunteers, psychiatric outpatients, and individuals exposed to childhood trauma or the World Trade Center attacks. Specific patient characteristics (e.g., treatment-refractory, first-episode psychosis) are sometimes mentioned.

Dosage:

Specific dosages mentioned include: CBD (single 400mg or 600mg; 600-1200mg/day; 30mg/day; 150-300mg/day; 200-800mg/day; up to 100mg/day; 1000mg/day; 600mg/day; fixed 300mg), THC (vaporizer 2mg & 4mg; oral 7.5mg & 12.5mg; sublingual 5mg twice daily), Dronabinol (synthetic THC) (oral 5mg; 2.5, 5, 10mg daily; 5mg & 10mg). Administration methods mentioned include oral, sublingual, vaporizer, smoked flower, ingested edible, oil capsules, tincture, soft gel capsules. Dose-dependent effects (e.g., low-dose THC anxiolytic, high-dose anxiogenic) and influence of CBD:THC ratio are noted.

Study Quality Assessment:

The text cites various study types: systematic reviews, meta-analyses, randomized controlled trials (RCTs, including double-blind, placebo-controlled, multicenter), cross-sectional studies, epidemiological studies, cohort studies, longitudinal studies, open-label studies, case reports/series, observational studies, postmortem studies, genetic studies, and neuroimaging studies (SPECT, PET, fMRI). It notes limitations such as preliminary results, equivocal/weak/mixed/conflicting evidence, small sample sizes, short duration of therapy, lack of reliable follow-up, potential confounding factors, and differences in methodology (doses, THC/CBD content, administration modes). Several ongoing/registered clinical trials (referenced by ClinicalTrials.gov identifiers) are mentioned.

All Effects:

PTSD anxiety depression mental disorders psychosis

This systematic review and meta-analysis examined the efficacy and safety of medicinal cannabis, compared with any control, as an intervention for depression, anxiety, and stress symptoms in people living with cancer

adverse events anxiety appetite +2 more

Findings:

This systematic review and meta-analysis found insufficient evidence for the efficacy and safety of medicinal cannabis for depression, anxiety, or stress in people with cancer. No clinically significant effects were found for these primary outcomes. Higher-dose synthetic THC was associated with increased anxiety events (very low confidence) and possibly increased adverse events (very low confidence), while medicinal cannabis (THC, CBD, whole-plant) improved appetite (moderate confidence) and reduced appetite loss severity (very low confidence).

Participants:

N = 1898 total participants; 100 % ≥18 years of age, people living with any cancer type.

Dosage:

Compared low versus high Δ9-tetrahydrocannabinol (THC) dose. Examined THC (70% synthetic), synthetic cannabidiol (with or without THC), and whole-plant extracts. Higher-dose synthetic THC effects mentioned.

Study Quality Assessment:

Systematic review and meta-analysis of intervention studies (n=15 studies: 11 randomized trials, 4 non-randomized trials). Databases searched systematically (inception to May 2023) plus snowball search. Data pooled using Review Manager. Evidence appraised using Cochrane risk of bias tools. Confidence assessed using GRADE. Limitations acknowledged: some studies had high or unclear risk of bias, imprecise pooled estimates, very low confidence in some findings.

All Effects:

adverse events anxiety appetite depression stress

Similar Nootropics

Berberine supplement image

Berberine

L-Theanine supplement image

L-Theanine

Ashwagandha supplement image

Ashwagandha

Holy Basil supplement image

Holy Basil